{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:49Z","timestamp":1786650109933,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Drug-eluting coronary stents with ultrathin struts and biodegradable polymers have been shown to reduce inflammation, neointimal proliferation, and thrombus formation, leading to less early and late complications in patients with coronary artery disease as compared to thinner strut and durable polymer second-generation stents. In Oman, currently, second-generation stents are used for all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this feasibility study was to evaluate the clinical safety and performance of ultrathin-strut (60 \u03bcm) biodegradable polymer-coated sirolimus-eluting stents in an all-comers patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a prospective, observational, single-center, and single-arm investigator-initiated study from August 2018 to August 2019. Inclusion criteria: 18 years of age, patients with symptomatic coronary artery disease indicated for percutaneous coronary intervention, and stenting of at least one coronary lesion. All patients were followed clinically or telephonically at 12 months after the index procedure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 88 patients were recruited in the study, but 10 patients were lost to follow-up and hence excluded from the analysis. The overall mean age was 63 \u00b1 13 years and 78% were males. The main comorbid conditions were hypertension (58%), diabetes mellitus (49%), and hyperlipidemia (26%). Fifty-three percent presented with unstable angina or non-ST elevation myocardial infarction (MI), 10% with ST elevation MI, recent MI 16%, 18% with stable angina, and 1.3% in cardiogenic shock. The mean left ventricular ejection fraction of the cohort was 46 \u00b1 14%. Angiographically, Type A lesions were seen in 25%, Type B in 32%, and Type C in 42%. Left anterior descending stenting was done in 44%, right coronary artery in 32%, left circumflex artery in 14%, left main in 5%, and graft stenting in 4%. Device success was 96%. Procedural success was seen in 97% of patients. At 1-year follow-up, 93% were asymptomatic; overall device-oriented clinical events were 6.8% including cardiac death in 2.7%, target-vessel MI in 2.7%, and target-lesion revascularization in 1.3% which all occurred in uncontrolled diabetic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>At index admission and 1 year, ultrathin-strut biodegradable polymer-coated sirolimus-eluting stent study showed low device-related adverse clinical events which are comparable to published data for the second-generation stents. This feasibility study shows that these stents can be used in all types of stent-indicated patients with added advantages of biodegradable polymer and ultrathin struts. In addition, measures to prevent, diagnose, and control diabetes need to be taken in Oman as this cohort of patients develop ST after stenting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/heartviews.heartviews_46_22","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T08:15:03Z","timestamp":1677053703000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Outcome of Ultrathin-Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents in Coronary Artery Disease Patients \u2013 A Feasibility Study"],"prefix":"10.4103","volume":"24","author":[{"given":"Prashanth","family":"Panduranga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzam","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240902","doi-asserted-by":"crossref","first-page":"e000064","DOI":"10.1136\/openhrt-2014-000064","article-title":"First-generation versus second-generation drug-eluting stents in current clinical practice: Updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients","volume":"1","author":"Navarese","year":"2014","journal-title":"Open Heart"},{"key":"R2-1-20240902","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","article-title":"Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious?","volume":"109","author":"Virmani","year":"2004","journal-title":"Circulation"},{"key":"R3-1-20240902","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R4-1-20240902","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jacc.2005.07.071","article-title":"Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project","volume":"47","author":"Nebeker","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R5-1-20240902","doi-asserted-by":"crossref","first-page":"e010028","DOI":"10.1136\/bmjopen-2015-010028","article-title":"Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry","volume":"6","author":"Lemos","year":"2016","journal-title":"BMJ Open"},{"key":"R6-1-20240902","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/eurheartj\/ehv203","article-title":"Report of a European Society of Cardiology-European Association of percutaneous cardiovascular interventions task force on the evaluation of coronary stents in Europe: Executive summary","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur Heart J"},{"key":"R7-1-20240902","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"R8-1-20240902","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.118.034456","article-title":"Newer-Generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease","volume":"138","author":"Bangalore","year":"2018","journal-title":"Circulation"},{"key":"R9-1-20240902","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4244\/EIJV9I12A234","article-title":"First-in-man randomised comparison of a novel sirolimus-eluting stent with abluminal biodegradable polymer and thin-strut cobalt-chromium alloy: INSPIRON-I trial","volume":"9","author":"Ribeiro","year":"2014","journal-title":"EuroIntervention"},{"key":"R10-1-20240902","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): A randomised, single-blind, non-inferiority trial","volume":"384","author":"Pilgrim","year":"2014","journal-title":"Lancet"},{"key":"R11-1-20240902","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","article-title":"Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: A pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials","volume":"33","author":"Stefanini","year":"2012","journal-title":"Eur Heart J"},{"key":"R12-1-20240902","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(19)31877-X","article-title":"Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): A single-blind, prospective, randomised superiority trial","volume":"394","author":"Iglesias","year":"2019","journal-title":"Lancet"},{"key":"R13-1-20240902","doi-asserted-by":"crossref","first-page":"e007331","DOI":"10.1161\/CIRCINTERVENTIONS.118.007331","article-title":"Subgroup analysis comparing ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in acute coronary syndrome patients","volume":"11","author":"Roguin","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"R14-1-20240902","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ihj.2012.07.011","article-title":"A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients","volume":"64","author":"Seth","year":"2012","journal-title":"Indian Heart J"},{"key":"R15-1-20240902","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4236\/ijcm.2014.55034","article-title":"Clinical performance of the cobalt-chromium biodegradable polymer coated sirolimus-eluting stent in an unselected real-world population?","volume":"5","author":"Chandwani","year":"2014","journal-title":"International Journal of Clinical Medicine"},{"key":"R16-1-20240902","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(18)31649-0","article-title":"Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): A multicentre, open-label, randomised non-inferiority trial","volume":"392","author":"]Lansky","year":"2018","journal-title":"Lancet"},{"key":"R17-1-20240902","doi-asserted-by":"crossref","first-page":"e026578","DOI":"10.1136\/bmjopen-2018-026578","article-title":"Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months\u2019 results from the S-FLEX UK registry","volume":"9","author":"Choudhury","year":"2019","journal-title":"BMJ Open"},{"key":"R18-1-20240902","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(18)32467-X","article-title":"Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): A prospective multicentre randomised controlled trial","volume":"393","author":"Zaman","year":"2019","journal-title":"Lancet"},{"key":"R19-1-20240902","doi-asserted-by":"crossref","first-page":"e010312","DOI":"10.1161\/CIRCINTERVENTIONS.120.010312","article-title":"Prospective multicenter randomized all-comers trial to assess the safety and effectiveness of the ultra-thin strut sirolimus-eluting coronary stent supraflex: Two-Year outcomes of the TALENT trial","volume":"14","author":"Gao","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"R20-1-20240902","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ccd.24374","article-title":"Impact of different stent alloys on human vascular response to everolimus-eluting stent: An optical coherence tomography study: The OCTEVEREST","volume":"81","author":"Guagliumi","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"R21-1-20240902","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1093\/eurheartj\/ehr182","article-title":"Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent versus a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: An optical coherence tomography substudy from the RESOLUTE All Comers trial","volume":"32","author":"Guti\u00e9rrez-Chico","year":"2011","journal-title":"Eur Heart J"},{"key":"R22-1-20240902","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jcin.2011.12.015","article-title":"Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: Evidence in vivo about the abluminal healing process","volume":"5","author":"Guti\u00e9rrez-Chico","year":"2012","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Heart Views"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/heartviews.heartviews_46_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:02:44Z","timestamp":1786647764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/heartviews.heartviews_46_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/heartviews.heartviews_46_22","relation":{},"ISSN":["1995-705X"],"issn-type":[{"value":"1995-705X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}